• OPEN AN ACCOUNT
Indian Indices
Nifty
22,529.05 27.05
(0.12%)
Sensex
73,953.31 -52.63
( -0.07%)
Bank Nifty
48,048.20 -151.30
( -0.31%)
Nifty IT
33,379.75 -59.00
( -0.18%)
Global Indices
Nasdaq
16,794.88 108.91
(0.65%)
Dow Jones
39,806.77 -196.82
(-0.49%)
Hang Seng
19,220.62 -415.60
(-2.12%)
Nikkei 225
38,946.93 -122.75
(-0.31%)
Forex
USD-INR
83.30 -0.18
(-0.21%)
EUR-INR
90.53 -0.23
(-0.25%)
GBP-INR
105.79 -0.01
(-0.01%)
JPY-INR
0.54 0.00
(-0.78%)

EQUITY - MARKET SCREENER

Colgate-Palmolive (India) Ltd
Industry :  Personal Care - Multinational
BSE Code
ISIN Demat
Book Value()
500830
INE259A01022
68.9138811
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
COLPAL
54.72
73188.61
EPS(TTM)
Face Value()
Div & Yield %
49.18
1
2.16
 

sun pharmaceuticals industries ltd
Sun Pharma proposes to acquire Taro
May 27,2023
Sun Pharmaceuticals Industries on 26 May 2023 has issued a letter to the Board of Directors of Taro Pharmaceutical Industries, Israel (Taro) with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share) (Proposed Transaction).

The Proposed Transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 (ICL) and practice. In this context, Purchaser shall form a wholly owned subsidiary (SPV), which shall enter into a merger agreement with Taro, with the SPV merging with and into Taro and Taro surviving the merger transaction. Consequently, Taro shall become a wholly owned subsidiary of Purchaser and be de-listed from NYSE.